MaxCyte, Inc. (MXCT) stock
MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value
$1.19+0.09 (+8.18%)
Close on Nov 12, 2026Market cap $122.82MP/E –Yield –
MaxCyte pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
No pe ratio figures for MaxCyte
MaxCyte has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?